Narrative review on PCSK9 inhibitors for familial hypercholesterolemia
Review explores PCSK9 inhibitors for familial hypercholesterolemia
This narrative review synthesizes evidence on PCSK9 inhibitors, including evolocumab, for familial hypercholesterolemia. The authors discuss…
This review looks at PCSK9 inhibitors like evolocumab for people with familial hypercholesterolemia. It discusses how these drugs work and t…
Phase 4 study of evolocumab safety and tolerability in renal transplant recipients
Can a new cholesterol drug help kidney transplant patients without causing harm?
This Phase 4 study evaluated the safety and tolerability of evolocumab, a PCSK-9 inhibitor, in renal transplant recipients at three hospital…
A new cholesterol injection kept kidney transplant patients safe for over two years without serious side effects, offering a potential alter…
Corrective re-analysis suggests Lp(a) reduction accounts for 57-70% of PCSK9 inhibitor benefit in ASCVD
Re-analysis suggests most PCSK9 inhibitor benefit comes from lowering Lp(a)
This Phase 3 corrective re-analysis of cardiovascular outcomes trial data in secondary prevention populations with ASCVD evaluated the role …
Researchers re-analyzed data from Phase 3 trials of alirocumab and evolocumab in patients with atherosclerotic cardiovascular disease.